Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.49 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.49 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.49 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 4/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HINT1 | P49773 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17357579 | 0.93 | P2RY11 (0.46) | P2RX3P2RX4P2RX2P2RY11SLC29A1 | |
| SCHEMBL8529895 | 0.85 | P2RY11 (0.54) | P2RX3P2RX4P2RX2P2RY11SLC29A1 | |
| SCHEMBL8529007 | 0.85 | SLC29A1 (0.50) | P2RY11SLC29A1ADORA2AADORA3ADORA1 | |
| SCHEMBL20058725 | 0.85 | HINT1 (0.46) | P2RX3P2RX4P2RX2P2RY11HINT1 | |
| SCHEMBL16870493 | 0.81 | TAS1R3 (0.57) | P2RX3P2RX4P2RX2P2RY11HINT1 | |
| SCHEMBL5621712 | 0.81 | P2RX3 (0.55) | P2RX3P2RX4P2RX2P2RY11ADORA2A | |
| SCHEMBL6758742 | 0.80 | P2RX3 (0.59) | P2RX3P2RX4P2RX2P2RY11HINT1 | |
| SCHEMBL8529274 | 0.79 | ALDH1A1 (0.53) | SLC29A1ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL6761729 | 0.79 | LMNA (0.58) | P2RX3P2RX4P2RX2P2RY11HINT1 | |
| SCHEMBL6761727 | 0.79 | LMNA (0.58) | P2RX3P2RX4P2RX2P2RY11HINT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150366888-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366888-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, TYMP | P2RX3 240/4885P2RX4 179/4885P2RX2 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.